MedTrace Logo

The Effect of Central Sensitization on Treatment Response in Patients With Fibromyalgia

NCT05020600 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-08-15

No results posted yet for this study

Summary

Central sensitization (CS) is as increased response to normal or sub-threshold stimuli of central nervous system and its close relationship with fibromyalgia has been demonstrated in several studies. However, the effect of initial CS severity on treatment response in these patients is not fully known. In this study, it was aimed to investigate the severity of CS and its effect on treatment response in patients with fibromyalgia.

Conditions

  • Central Sensitisation
  • Fibromyalgia

Interventions

DRUG

Duloxetine

First-line fibromyalgia treatment

DRUG

Pregabalin

First-line fibromyalgia treatment

DRUG

Amitriptyline

First-line fibromyalgia treatment

Sponsors & Collaborators

  • Marmara University

    lead OTHER

Principal Investigators

  • Canan SANAL TOPRAK, assoc. prof. · Marmara University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-19
Primary Completion
2024-06-01
Completion
2024-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05020600 on ClinicalTrials.gov